DDX3 expression was especially prominent in breast cancer brain metastases, with 65% of metastases having high DDX3 expression and 48% of patients having an increase as compared to their primary tumor (OR 15.0, 95% CI 3.29–68.34, p < 0.001, Table 1). Here, DDX3X is linked to neoplasm.